The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation (“CVS” or “the Company”) (NYSE: CVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between May 3, 2023 and April 30, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 10, 2024.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. CVS failed to properly forecast medical cost trends and health care utilization rates. The Company was forced to incur material costs due to its ineffective forecasts. The Company overstated the profitability of its Health Care Benefits division. Despite its assurances, the Company’s profits from other business segments were not sufficient to cover the increasing expenses incurred by the Health Care Benefits segment. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about CVS, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909959435/en/
